MX2024005057A - Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). - Google Patents
Anticuerpo de receptor 4 de efrina tipo a (anti-epha4).Info
- Publication number
- MX2024005057A MX2024005057A MX2024005057A MX2024005057A MX2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A MX 2024005057 A MX2024005057 A MX 2024005057A
- Authority
- MX
- Mexico
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- heavy chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021184126 | 2021-11-11 | ||
| PCT/JP2022/041723 WO2023085320A1 (ja) | 2021-11-11 | 2022-11-09 | 抗EphA4抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005057A true MX2024005057A (es) | 2024-05-10 |
Family
ID=86335794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005057A MX2024005057A (es) | 2021-11-11 | 2022-11-09 | Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240385190A1 (https=) |
| EP (1) | EP4431606A4 (https=) |
| JP (1) | JPWO2023085320A1 (https=) |
| KR (1) | KR20240099197A (https=) |
| CN (1) | CN118234864A (https=) |
| AU (1) | AU2022388189A1 (https=) |
| CA (1) | CA3235297A1 (https=) |
| MX (1) | MX2024005057A (https=) |
| TW (1) | TW202323286A (https=) |
| WO (1) | WO2023085320A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120988114A (zh) * | 2025-08-08 | 2025-11-21 | 上海领检科技有限公司 | 一种人源化IgE嵌合抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| JP5961608B2 (ja) | 2011-04-25 | 2016-08-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | EphA4細胞外ドメインの測定による認知機能障害を伴う神経系疾患の検出方法 |
| WO2017043466A1 (ja) * | 2015-09-08 | 2017-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗EphA4抗体 |
| JP6877419B2 (ja) * | 2015-10-27 | 2021-05-26 | ザ ユニバーシティー オブ クイーンズランド | 治療の方法およびそのために有用な剤 |
| AR119303A1 (es) * | 2019-07-01 | 2021-12-09 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 humano |
-
2022
- 2022-11-09 MX MX2024005057A patent/MX2024005057A/es unknown
- 2022-11-09 EP EP22892818.0A patent/EP4431606A4/en active Pending
- 2022-11-09 CA CA3235297A patent/CA3235297A1/en active Pending
- 2022-11-09 KR KR1020247013303A patent/KR20240099197A/ko active Pending
- 2022-11-09 AU AU2022388189A patent/AU2022388189A1/en active Pending
- 2022-11-09 WO PCT/JP2022/041723 patent/WO2023085320A1/ja not_active Ceased
- 2022-11-09 CN CN202280071642.3A patent/CN118234864A/zh active Pending
- 2022-11-09 TW TW111142711A patent/TW202323286A/zh unknown
- 2022-11-09 US US18/704,106 patent/US20240385190A1/en active Pending
- 2022-11-09 JP JP2023559866A patent/JPWO2023085320A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2023085320A1 (https=) | 2023-05-19 |
| US20240385190A1 (en) | 2024-11-21 |
| CA3235297A1 (en) | 2023-05-19 |
| TW202323286A (zh) | 2023-06-16 |
| KR20240099197A (ko) | 2024-06-28 |
| AU2022388189A1 (en) | 2024-05-02 |
| CN118234864A (zh) | 2024-06-21 |
| EP4431606A4 (en) | 2025-11-26 |
| WO2023085320A1 (ja) | 2023-05-19 |
| EP4431606A1 (en) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2641294T3 (es) | Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer | |
| MX2022015133A (es) | Anticuerpo humanizado anti-receptor de igf-1. | |
| CO2017010316A2 (es) | Anticuerpo monoclonal aislado y / o recombinante y un método para identificar la infección por el virus de chikungunya glycoprotein e2 mediante el contacto con una muestra con un anticuerpo o fragmento de anticuerpos con secuencias cdr de cadena pesada y ligera | |
| ES2566501T3 (es) | Detección del consumo de cannabis | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| PE20251579A1 (es) | Anticuerpos especificos para cd70 y sus usos | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| RU2016116773A (ru) | Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы | |
| PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| EP4675278A3 (en) | Assay for plasma cell associated disease | |
| MX2024001067A (es) | Composicion farmaceutica y uso. | |
| BR112018007842A2 (pt) | imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk) | |
| NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| PE20180576A1 (es) | ANTICUERPOS MONOCLONALES ESPECIFICOS PARA EL ANTIGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, UTILES PARA LA DETECCION Y EL DIAGNOSTICO DE LA INFECCION CAUSADA POR VRSh | |
| WO2018167141A3 (en) | Target detection using a monovalent antibody | |
| MX2024005057A (es) | Anticuerpo de receptor 4 de efrina tipo a (anti-epha4). | |
| PE20200173A1 (es) | Anticuerpos anti-trkb | |
| EA201891990A1 (ru) | Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна | |
| AR087485A1 (es) | Anticuerpos de union a fosforilcolina (pc) y/o conjugados de pc | |
| AR117548A1 (es) | Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv | |
| EA201692071A1 (ru) | Иммуноанализ и антитела для обнаружения хромогранина а |